請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37652
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林中天 | |
dc.contributor.author | Nien-Ting Lin | en |
dc.contributor.author | 林念庭 | zh_TW |
dc.date.accessioned | 2021-06-13T15:36:58Z | - |
dc.date.available | 2008-07-24 | |
dc.date.copyright | 2008-07-24 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-10 | |
dc.identifier.citation | 1. Adamis AP, Shima DT. 2005. The role of vascular endothelial growth factor in ocular health and disease. Retina 25:111-8.
2. Adamis AP, Meklir B, Joyce NC. 1991. In situ injury-induced release of basic-fibroblast growth factor from corneal epithelial cells. Am J Pathol. 139(5):961-7. 3. Aiello LP, Pierce EA, Foley ED, Takagi H, Chen H, Riddle L, Ferrara N, King GL, Smith LE. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 92(23):10457-61. 4. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. 1998. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39:18-22. 5. Andreoli CM, Miller JW. 2007. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 18:502-8. 6. Auerbach R, L:ewis R, Shinners B, Kubai L, Akhtar N. 2003. Angiogenesis assays: A critical overview. Clin Chem 49(1):32-40. 7. Auguste P, Gursel DB, Lemiere S, Reimers D, Cuevas P, Carceller F, Di Santo JP, Bikfalvi A. 2001. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res 61:1717–26. 8. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. 2006. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-72 e365. 9. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. 2008. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 27:142-7. 10. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. 2008. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 33:23-8. 11. Bakri SJ, Cameron JD, McCannel CA, Pulido JS, Marler RJ. 2006. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol 142:162-4. 12. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. 2007. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855– 9. 13. Barros LF, Belfort R, Jr. 2007. The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 79:389-94. 14. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. 2008. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 145(2):249-256. 15. Bhuvaneswari R, Yuen GY, Chee SK, Olivo M. 2007. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins. Photochem Photobiol Sci. 6(12):1275-83. 16. Binetruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, Plouet J, Derbin C, Perret G, Mazie JC. 2000. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 19:1525-33. 17. Bock F, Konig Y, Kruse F, Baier M, Cursiefen C. 2008. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 246:281-4. 18. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G, Cursiefen C. 2007. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48:2545-52. 19. Burger PC, Chandler DB, Klintworth GK. 1985. Experimental corneal neovascularization: biomicroscopic, angiographic, and morphologic correlation. Cornea. 4(1):35-41. 20. Castellon R, Hamdi HK, Sacerio I, Aoki AM, Kenney MC, Ljubimov AV. 2002. Effects of angiogenic growth factor combinations on retinal endothelial cells. Exp Eye Res 74:523–35. 21. Cenni E, Perut F, Granchi D, Avnet S, Amato I, Brandi ML, Giunti A, Baldini N. 2007. Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma. Anticancer Res. 27(1A):315-9. 22. Chang JH, Gabison EE, Kato T, Azar DT. 2001. Corneal neovascularization. Curr Opin Ophthalmol 12:242-9. 23. Chang L, Kaipainen A, Folkman J. 2002. Lymphangiogenesis new mechanisms. Ann N Y Acad Sci 979:111–9 24. Chen L, Hamrah P, Cursiefen C, Zhang Q, Pytowski B, Streilein JW, Dana MR. 2004. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat Med. 10(8):813-5. 25. Chilov MN, Grigg JR, Playfair TJ. 2007. Bevacizumab (Avastin) for the treatment of neovascular glaucoma. Clin Experiment Ophthalmol 35:494-6. 26. Cursiefen C, Cao J, Chen L, Maruyama K, Jackson D, Kruse FE, Wiegand SJ, Dana MR, Streilein JW. 2004. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 45:2666-73. 27. Cursiefen C, Kuchle M, Naumann GO. 1998. Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea. 17(6):611-3. 28. Cursiefen C, Rummelt C, Kuchle M. 2000. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 19:526-33. 29. Cursiefen C, Maruyama K, Jackson DG, Strilein JW, Kruse FE. 2006. Time course of angiogenesis and lympahngiogenesis after brief corneal inflammation. Cornea 25(4):443-7. 30. DeStafeno JJ, Kim T. 2007. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 125(6):834-6. 31. Erdurmus M, Totan Y. 2007. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 245(10):1577-9. 32. Ferrara N, Hillan KJ, Novotny W. 2005. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophy Res Comm 333:328-35. 33. Folkman J, Shing Y. 1992. Angiogenesis. J Biol Chem. 5;267(16):10931-4. 34. Gabler C, Plath-Gabler A, Killian GJ, Berisha B, Schams D. 2004. Expression pattern of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) system members in bovine corpus luteum endothelial cells during treatment with FGF-2, VEGF or oestradiol. Reprod Domest Anim 39:321-7. 35. Gan L, Fagerholm P. 2001. Leukocytes in the early events of corneal neovascularization. Cornea.20(1):96-9. 36. Gan L, Fagerholm P, Palmblad J. 2004. Vascular endothelial growth factor (VEGF) and its receptor VEGF-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol 82:557-63. 37. Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Xiao WH, Duh EJ, Yang HS, Lai H, Kovesdi I, Carrion M, Wei L, Campochiaro PA. 2003. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum Gene Ther. 14(2):129-41. 38. Haroon ZA, Amin K, Saito W, Wilson W, Greenberg CS, Dewhirst MW. 2002. SU5416 delays wound healing through inhibition of TGF-beta 1 activation. Cancer Biol Ther. 1(2):121-6. 39. Hayashi N, Nakayasu K, Okisaka S. 1996. Immunohistochemical localization of acidic and basic fibroblast growth factor through corneal neovascularization in vivo and in vitro. Nippon Ganka Gakkai Zasshi. 100(8):587-91. 40. Haynes WL, Proia AD, Klintworth GK. 1989. Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophthalmol Vis Sci 30:1588-93. 41. Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U; Tubingen Bevacizumab Study Group. 2007. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48:2814-23. 42. Herbert JM, Laplace MC, Maffrand JP. 1988. Effect of heparin on the angiogenic potency of basic and acidic fibroblast growth factors in the rabbit cornea assay. Int J Tissue React 10:133–9. 43. Hicklin DJ, Ellis LM. 2005. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 10;23(5):1011-27. 44. Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, Noori F. 2007. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Experiment Ophthalmol 35:745-8. 45. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-42. 46. Ignoffo RJ. 2004. Overview of bevacizumab: A new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health-Syst Pharm 61(Suppl5):S21-6. 47. Javerzat S, Auguste P, Bikfalvi A. 2002. The role of fibroblast growth factors in vascular development. Trends Mol Med 8: 483–9. 48. Joussen AM, Kruse FE, Volcker HE, Kirchhof B. 1999. Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol 237:920-7. 49. Kanda S, Miyata Y, Kanetake H. 2004. Fibroblast growth factor-2-mediated capillary morphogenesis of endothelial cells requires signals via Flt-1/vascular endothelial growth factor receptor-1: possible involvement of c-Akt. J Biol Chem 279:4007-16. 50. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. 1996. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci. 37(8):1625-32. 51. Kim B, Tang Q, Biswas PS, Xu J, Schiffelers RM, Xie FY, Ansari AM, Scaria PV, Woodle MC, Lu P, Rouse BT. 2004. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol. 165(6):2177-85. 52. Kim JH, Kim JC, Shin SH, Chang SI, Lee HS, Chung SI. 1999. The inhibitory effects of recombinant plasminogen kringle 1-3 on the neovascularization of rabbit cornea induced by angiogenin, bFGF, and VEGF. Exp Mol Med. 31(4):203-9. 53. Kim TI, Kim SW, Kim S, Kim T, Kim EK. 2008. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea. 27(3):349-52. 54. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW. 2002. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 120(3):338-46. 55. Kvanta A, Algvere PV, Berglin L, Seregard S. 1996. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 37(9):1929-34. 56. Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B. 2000. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 70:419-28. 57. Kwon YS, Kim JC. 2006. Inhibition of corneal neovascularization by rapamycin. Exp Mol Med. 38(2):173-9. 58. Lee P, Wang CC, Adamis AP. 1998. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 43(3):245-69. 59. Lepri A, Benelli U, Bernardini N, Bianchi F, Lupetti M, Danesi R, Del Tacca M, Nardi M.. 1994. Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. J Ocul Pharmacol 10:273-80. 60. Lin YS, Nguyen C, Mendoza LJ, Escandon E, Fei D, Meng YG, Modi NB. 1999. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371-8. 61. Lipman RM, Epstein RJ, Hendricks RL. 1992. Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol 110:405-7. 62. Lohela M, Saaristo A, Veikkola T, Alitalo K. Lymphangiogenic growth factors, receptors and therapies. Thromb Haemost. 90(2):167-84. 63. Luthra S, Narayanan R, Marques E, Chwa M, Kim DW, Dong J, Seigel GM, Neekhra A, GramajoAL, Brown DJ, Kenney MC, Kuppermann BD. 2006. Evaluation of in vitro effects of bevacizumab (avstin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 26(5):512-8. 64. Ma DH, Chen JK, Zhang F, Lin KY, Yao JY, Yu JS. 2006. Regulation of corneal angiogenesis in limbal stem cell deficiency. Prog Retin Eye Res 25:563-90. 65. Manzano RP, Peyman GA, Khan P, Kivilcim M. 2006. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26:257-61. 66. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC, Chevez-Barrios P. 2007. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91:804-7. 67. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. 2005. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 112:1035-47. 68. Mochimaru H, Usui T, Yaguchi T, Nagahama Y, Hasegawa G, Usui Y, Shimmura S, Tsubota K, Amano S, Kawakami Y, Ishida S. 2008. Suppression of alkali burn-induced corneal neovascularization by dendritic cell vaccination targeting VEGF receptor 2. Invest Ophthalmol Vis Sci. 49(5):2172-7. 69. Mohan R, Sivak J, Ashton P, Russo LA, Pham BQ, Kasahara N, Raizman MB, Fini ME. 2000. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem. 7;275(14):10405-12. 70. Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA. 2005. Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 89:1368-70. 71. Nguyen QD, Shah SM, Hafiz G, Do DV, Haller JA, Pili R, Zimmer-Galler IE, Janjua K, Symons RC, Campochiaro PA. 2008. Intravenous Bevacizumab Causes Regression of Choroidal Neovascularization Secondary to Diseases Other Than Age-related Macular Degeneration. Am J Ophthalmol 145:257-66. 72. Ormerod LD, Garsd A, Reddy CV, Gomes SA, Abelson MB, Kenyon KR. 1989. Dynamics of corneal epithelial healing after an alkali burn. A statistical analysis. Invest Ophthalmol Vis Sci 30:1784-93. 73. Otasevic L, Gong N, Ritter T, Mergler S, Pleyer U. 2007. Effects of spironolactone on corneal allograft survival in the rat. Ophthalmic Res. 39(6):325-9. 74. Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K. 2000. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol. 156(5):1499-504. 75. Pepper MS, Ferrara N, Orci L, Montesano R. 1992. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 189:824-31. 76. Peyman GA, Kazi AA, Riazi-Esfahani M, Aydin E, Kivilcim M, Sanders DR. 2006. The effect of combinations of flurbiprofen, low molecular weight heparin, and doxycycline on the inhibition of corneal neovascularization. Cornea. 25(5):582-5. 77. Philipp W, Speicher L, Humpel C. 2000. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41:2514-22. 78. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. 2005. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16:159-78. 79. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP. 2001. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 42(10):2408-13. 80. Rebuzzi L, Willmann M, Sonneck K, Gleixner KV, Florian S, Kondo R, Mayerhofer M, Vales A, Gruze A, Pickl WF, Thalhammer JG, Valent P. 2007. Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. Vet Immunol Immunopathol. 115(3-4):320-33. 81. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr, Gonzalez S, Feuer WJ, Lin RC, Lalwani GA, Nguyen JK, Kumar G. 2006. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 26(5):495-511. 82. Rosenfeld PJ, Fung AE, Puliafito CA. 2005. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336-9. 83. Sarayba MA, Li L, Tungsiripat T, Sweet PM, Patel AJ, Osann KE, Chittiboyina A, Benson SC, Pershadsingh HA, Chuck RS. 2005. Inhibition of corneal neovascularization by a peroxisome proliferators-activated receptor-γ ligand. Exp Eye Res 80:435-42. 84. Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin H; Diabetic Retinopathy Clinical Research Network Study Group. 2008. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Retina 28:36-40. 85. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, Shapiro RL, Galloway AC, Rifkin DB, Mignatti P. 1998. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 141:1659-73. 86. Seta F, Patil K, Bellner L, Mezentsev A, Kemp R, Dunn MW, Schwartzman ML. 2007. Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1. Prostaglandins Other Lipid Mediat. 84(3-4):116-27. 87. Shen BQ, Lee DY, Zioncheck TF. 1999. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J Biol Chem. 274(46):33057-63. 88. Shi W, Gao H, Xie L, Wang S. 2006. Sustained intraocular rapamycin delivery effectively prevents high-risk corneal allograft rejection and neovascularization in rabbits. Invest Ophthalmol Vis Sci 47:3339-44. 89. Spitzer MS, Wallenfels-Thilo B, Sierra A, Yoeruek E, Peters S, Henke-Fahle S, Bartz-Schmidt KU, Szurman P; Tuebingen Bevacizumab Study Group. 2006. Antiproliferative and cytotoxic properties of bevacizumab (avastin) on different ocular cells. Br. J. Ophthalmol. 90(10):1316-21. 90. Tille JC, Wood J, Mandriota SJ, Schnell C, Ferrari S, Mestan J, Zhu Z, Witte L, Pepper MS. 2001. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro. J Pharmacol Exp Ther 299:1073–85. 91. Wijnggaarden P, Closter DJ, Williams KA. Inhibitors of ocular neovascularization. J Am Vet Med Asso 293(12):1509-13, 2006. 92. Witmer AN, van Blijswijk BC, Dai J, Hofman P, Partanen TA, Vrensen GF, Schlingemann RO. 2001. VEGFR-3 in adult angiogenesis. J Pathol. 195(4):490-7. 93. Wu PC, Yang LC, Kuo HK, Huang CC, Tsai CL, Lin PR, Wu PC, Shin SJ, Tai MH. 2005. Inhibition of corneal angiogenesis by local application of vasostatin. Mol Vis. 11:28-35. 94. Xue L, Greisler HP. 2002. Angiogenic effect of fibroblast growth factor-1 and vascular endothelial growth factor and their synergism in a novel in vitro quantitative fibrin-based 3-dimensional angiogenesis system. Surgery 132:259–67. 95. Yamagami S, Dana MR. 2001. The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci. 42(6):1293-8. 96. Yamagami S, Dana MR, Tsuru T. 2002. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea. 21(4):405-9. 97. Yaylali V, Ohta T, Kaufman SC, Maitchouk DY, Beuerman RW. 1998. In vivo confocal imaging of corneal neovascularization. Cornea. 17(6):646-53 98. Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P. 2007. Safety profile of bevacizumab on cultured human corneal cells. Cornea 26:977-982. 99. Zakarija A, Soff G. 2005. Update on angiogenesis inhibitors. Curr Opin Oncol 17:578-83. 100. Zhang Z, Ma JX, Gao G, Li C, Luo L, Zhang M, Yang W, Jiang A, Kuang W, Xu L, Chen J, Liu Z. 2005. Plasminogen kringle 5 inhibits alkali-burn-induced corneal neovascularization. Invest Ophthalmol Vis Sci 46:4062-71. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/37652 | - |
dc.description.abstract | 正常眼角膜構造為透明無血管生長,當發生感染、炎症、乾眼症等角膜疾病時,眼角膜常會出現許多新生血管生成,過多的新生血管會導致炎症反應加劇,且導致眼角膜的透明度降低或喪失。血管內皮生長因子(vascular endothelium growth factor, VEGF) 在其中扮演了非常重要的角色,我們實驗以抗血管內皮生長因子(Anti-VEGF)藥物來拮抗血管內皮生長因子的作用進而阻斷角膜新生血管作用。實驗使用紐西蘭白兔進行體內試驗,我們以三種模式來建立角膜新生血管:角膜微晶格模式、角膜輪狀部幹細胞缺損模式及角膜化學灼傷模式。抗血管內皮生長因子藥物選擇Bevacizumab (Avastin | zh_TW |
dc.description.abstract | The cornea is an avascular transparent structure normally. Corneal neovascularization may be initiated following infection, trauma, and inflammation, leading to decreased corneal transparency. Additionally, corneal neovascularization is a risk factor for graft rejection after allograft corneal transplantation. Vascular endothelium growth factor (VEGF) is known to have an important role in angiogenesis in the body. The anti-VEGF drugs have been proved to inhibit VEGF in previous reports on cancers and retina. In this study, we investigated the effects of anti-VEGF drug on corneal neovascularization in a rabbit model. Three models of corneal neovascularization in rabbits were used in this study, namely corneal micropocket, limbal stem cell insufficiency, and chemical burn. The anti-VEGF drug, bevacizumab (Avastin), was injected subconjunctivally for treating corneal neovascularization in these rabbit models. The maximal length and area of corneal neovascularization were measured and recorded. Histology analysis and immunochemical staining of the rabbit cornea were performed. Bevacizumab revealed inhibitory effect of corneal neovascularization in all of the three models. The treatment group showed lesser corneal neovascularization, inflammatory cells infiltration, and vascular endothelium cells by histology. Immunochemical stain revealed the expressions of the vascular endothelial cells and bevacizuzmab in cornea. In conclusion, subconjunctival injection of anti-VEGF drug, bevacizumab, can effectively suppress corneal neovascularization with no significant side effects based on this study. The dosage, administration routes, and efficacy in corneal diseases and allografts remains to investigate in the future. | en |
dc.description.provenance | Made available in DSpace on 2021-06-13T15:36:58Z (GMT). No. of bitstreams: 1 ntu-97-R94629025-1.pdf: 2063242 bytes, checksum: f929cf44ac44539dff51c886650a25fc (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 目錄
口試委員會審定書 i 致謝 ii 中文摘要 iii 英文摘要 iv 第一章 緒論 1 第一節 角膜新生血管 1 第二節 角膜新生血管之治療 2 第三節 研究目的 2 第二章 文獻探討 3 第一節 角膜新生血管之生理機制 3 第二節 角膜新生血管之治療 6 第三節 抗血管內皮生長因子藥物 7 第三章 實驗材料與方法 10 第一節 實驗材料 10 第二節 實驗方法 10 一、 角膜微晶格模式 10 二、 角膜輪狀部幹細胞缺損模式 11 三、 角膜化學灼傷模式 12 四、 組織病理學 12 五、 統計分析方法 13 第四章 實驗結果 14 第一節 角膜微晶格模式 14 第二節 角膜輪狀部幹細胞缺損模式 14 第三節 角膜化學灼傷模式 15 第四節 組織病理學 15 第五章 討論 17 第一節 血管內皮生長因子在角膜新生血管作用參與機制及治療成果 17 第二節 纖維母細胞生長因子在角膜新生血管作用參與機制及治療成果 18 第三節 角膜新生血管模式比較 20 第四節 Bevacizumab控制角膜新生血管的效果及在角膜的分布狀況 22 第五節 角膜新生血管在獸醫的發展 25 第六節 Bevacizumab的副作用研究 26 第六章 結論 28 參考文獻 29 圖目錄 37 表目錄 47 | |
dc.language.iso | zh-TW | |
dc.title | 抗血管內皮生長因子藥物Bevacizumab對抑制角膜新生血管之影響 | zh_TW |
dc.title | Inhibitory Effect of Anti-VEGF Drugs Bevacizumab (Avastin) on Corneal Neovascularization | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 陳偉勵 | |
dc.contributor.oralexamcommittee | 劉振軒,葉力森 | |
dc.subject.keyword | 角膜,新生血管,血管內皮生長因子,癌思停, | zh_TW |
dc.subject.keyword | cornea,neovascularization,vascular endothelium growth factor (VEGF),bevacizumab, | en |
dc.relation.page | 50 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2008-07-10 | |
dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
顯示於系所單位: | 獸醫學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 2.01 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。